Open AccessCORR® ORS Richard A. Brand Award: Disruption in Peroxisome Proliferator-Activated Receptor-γ (PPARG) Increases Osteonecrosis Risk Through Genetic Variance and Pharmacologic Modulation
Author(s) -
Cody C. Wyles,
Christopher R. Paradise,
Matthew T. Houdek,
Susan L. Slager,
André Terzic,
Atta Behfar,
André J. van Wijnen,
Rafael J. Sierra
Publication year - 2019
Publication title -
clinical orthopaedics and related research
Language(s) - English
Resource type - Journals
eISSN - 1528-1132
pISSN - 0009-921X
DOI - 10.1097/corr.0000000000000713
Subject(s) - medicine , peroxisome proliferator activated receptor gamma , single nucleotide polymorphism , cohort , genome wide association study , bioinformatics , oncology , genetics , genotype , peroxisome proliferator activated receptor , gene , biology , receptor
The pathophysiology of osteonecrosis of the femoral head (ONFH) is poorly understood, and the diagnosis is idiopathic in as many as 40% of patients. Genetic and epigenetic etiologies have been postulated, yet no single nucleotide polymorphisms (SNPs) with intuitive biologic implications have been elucidated.